PETS PETMED EXPRESS INC Insider Trading

Nina Capital Holdings (10% Owner) buys 25,000 shares of PETS at $1.75; stock down -60.4% from 52-week high, insider's 5 prior PETS trades yielded 0 of 5 gains at 90-day mark.

Nina Capital Holdings purchased 25,000 shares of PetMed Express at $1.75, bringing its total stake to 2,600,000 shares. However, the stock has declined -25.0% in the past 30 days and -31.3% over 90 days, trading at $1.71 (currently -60.4% from its 52-week high of $4.32). The company's fundamentals are deteriorating: annual revenue growth was -21.1% and the company posted a net loss of $10,553,000 on quarterly revenue of $40,660,000, with full-year results also negative. Notably, this is the insider's sixth buy at PETS, yet the prior five purchases at this ticker all produced losses at the 90-day mark (0 of 5 well-timed), and the insider's broader cross-ticker track record shows a 90-day win rate of only 7.69% with an average 90-day return of -15.0%. The pattern of repeated purchases into a declining stock with deteriorating fundamentals and a history of failed buy timing at this specific ticker suggests limited insight into inflection points.

10% owner Silvercape Investments buys 101,000 shares of PETS at $3.17 after recent similar purchases; stock -53.0% from 52-week high

Silvercape Investments, a 10% owner, purchased 101,000 shares at $3.17 on 2025-08-13, adding to a pattern of five prior purchases at PETS within the preceding six weeks (2025-07-01 through 2025-08-01). The current price of $3.10 is down -53.0% from the 52-week high of $6.60, and the stock has declined -19.7% over the past 90 days. PETS reports -$707,000 net income on $53.0M quarterly revenue, with a trailing P/E of 155 and a market cap of $64.0M, indicating the company remains unprofitable on a full-year basis despite +9.4% revenue growth. The repeated accumulation at depressed prices—now at $3.17 following buys at $3.02 and lower on prior dates—warrants examination of whether this reflects conviction in a turnaround or mechanical accumulation within a pre-established plan.

10% owner Silvercape Investments Ltd bought 118,200 shares of PETS at $3.21 on 2025-08-01; stock down -51.5% from 52-week high of $6.60.

Silvercape Investments Ltd, a 10% owner, purchased 118,200 shares (raising holdings by +5.0% to 2.48M shares) at $3.21, bringing total transaction value to $379,422.00. The stock is currently trading at $3.20, having declined -51.5% from its 52-week high of $6.60 and fallen -9.6% over the past 90 days. The company reported revenue of $53.0M in its latest quarter but remains unprofitable with a net loss of $-707.0K, warranting scrutiny given the elevated P/E ratio of 160.00. Reviewing Silvercape's prior trades at PETS, five recent buys (spanning 2025-05-20 through 2025-07-18) have shown mixed results: a buy on 2025-07-02 returned +0.6% at 30 days, while a buy on 2025-05-20 returned -13.4% at 30 days. The pattern of multiple accumulations in rapid succession, combined with the stock's sustained decline from its 52-week peak and the company's ongoing unprofitability, suggests the filing warrants deeper investigation into the company's operational trajectory and whether this sustained buying pattern reflects a contrarian conviction or responds to other factors.

10% Owner NINA CAPITAL HOLDINGS INC. bought 25,000 shares of PETS at $3.50 (2025-07-21); stock now $3.51, down 46.8% from 52-week high.

NINA CAPITAL HOLDINGS INC., a 10% shareholder, purchased 25,000 shares at $3.50 on 2025-07-21, increasing holdings from 2,550,000 to 2,575,000 shares. This continues a pattern of repeated open-market purchases: five prior buys at PETS occurred between 2025-03-03 and 2025-06-03, with measurable 90-day outcomes on three of those trades showing 0 of 3 well-timed (returns of -11.9%, -3.6%, and -14.4%). The insider's broader cross-ticker track record shows 12 prior open-market buys with an average 90-day return of -12.3% and a 10.00% win rate. Fundamentally, PetMed Express reported quarterly revenue of $52,984,000.00 and a loss of $-707,000.00, with the company unprofitable over its most recent full fiscal year; the stock trades at a P/E of 175.50 and is currently 46.8% below its 52-week high. The repeated buying activity from a significant shareholder in a loss-making company with weak recent timing outcomes presents a mixed signal: while insider ownership concentration may suggest committed belief, the track record of negative outcomes on prior purchases at this ticker and the negative win rate on cross-ticker buys warrant careful attention to execution and market conditions.

Silvercape Investments (10% owner) buys 17,565 PETS shares at $3.23; stock now at $3.41, -48.3% from 52-week high.

Silvercape Investments, holding 2.36M shares of PETMED EXPRESS, purchased 17,565 additional shares at $3.23 on 2025-07-18, adding 0.7% to its stake. The company is unprofitable (full-year net income was negative, most recent quarter net income was $-707,000), trades at an elevated P/E of 170.50, and the stock is down 48.3% from its 52-week high, though it has recovered +5.2% over the past 30 days and +8.6% over 90 days. Notably, Silvercape has made four separate purchases at PETS in rapid succession (2025-05-20, 2025-07-01, 2025-07-02, and 2025-07-17), with only the May 20 purchase showing a measurable 30-day outcome of -13.4% — consistent with the insider's broader cross-ticker track record of -13.4% average 30-day returns on prior buys. This pattern of repeated purchases during a period of continued selling pressure and near-term negative returns warrants tracking to discern whether this represents a contrarian accumulation thesis or a sequence of poorly-timed entries.

10% owner Silvercape buys 31,701 PETS shares at $3.15; 4 consecutive buys in 2.5 weeks amid -49.8% drop from 52-week high

Silvercape Investments, a 10% holder, purchased 31,701 shares at $3.15 on 2025-07-17, expanding its position by +1.4% to 2,342,931 shares. This is the fourth consecutive open-market buy at PETS in 17 days (purchases on 2025-05-20, 2025-07-01, 2025-07-02, and 2025-07-17), all while the stock trades 49.8% below its 52-week high of $6.60. The company is unprofitable (net income of $-707,000 over the latest quarter) despite 9.4% annual revenue growth, with a stretched P/E of 165.50. Silvercape's cross-ticker open-market buy history shows an average 30-day return of -13.4%, and its single measurable same-ticker buy (2025-05-20) also declined 13.4% over 30 days. The pattern of repeated purchases into a depressed stock price warrants monitoring of the insider's conviction thesis versus realized outcomes.

10% owner Silvercape Investments bought 2,817 shares of PETS at $3.22 on 2025-07-02, adding to holdings post-recent buying.

Silvercape Investments Ltd, holding 2,311,230 shares post-transaction (10% owner), purchased 2,817 shares at $3.22, continuing a pattern of modest accumulation—a buy on 2025-07-01 immediately preceded this transaction. However, the prior buy at this ticker on 2025-05-20 at $3.22 showed a -13.4% 30-day return, and the stock now trades -50.2% from its 52-week high and -16.7% over the past 30 days, suggesting deteriorating market conditions since the earlier purchase. PETS is unprofitable (full-year net income was negative, latest quarter net income $-707,000.00) despite +9.4% annual revenue growth, and carries an elevated P/E of 164.50. The small purchase size relative to holdings (+0.1%) does not signal material new conviction; rather, it reflects incremental positioning in a declining stock where the insider's prior recent transaction has not yet generated measurable returns.

10% owner Silvercape Investments bought 694 shares of PETS at $3.21 on 2025-07-01; stock down -48.9% from 52-week high, company unprofitable.

Silvercape Investments, a 10% shareholder, purchased 694 shares at $3.21, a small absolute addition to its 2.31M share position. The timing coincides with a significant drawdown: PETS is trading -48.9% from its 52-week high of $6.60 and down -11.8% over the prior 30 days. The company's fundamentals remain challenged—it reported a net loss of -$707,000.00 in the latest quarter, operates with a P/E of 168.50, and generated annual revenue of $53.0M with only +9.4% year-over-year growth. Silvercape's own track record across tickers shows an average 30-day return of -13.4% on prior buys, and at this ticker specifically, a prior May buy returned -13.4% over 30 days, suggesting limited success timing market entries. The small size of this purchase (0.0% increase to holdings) and the absence of measurable outcomes on prior PETS transactions limit the strength of any signal this trade conveys.

10% Owner NINA CAPITAL HOLDINGS purchases 25,000 shares of PETS at $3.94; stock -40.3% from 52-week high, insider's PETS trades 0 of 2 well-timed at 90-day mark.

NINA CAPITAL HOLDINGS acquired 25,000 shares at $3.94 on 2025-06-03, increasing holdings to 2,550,000 shares. This is the insider's sixth transaction in PETS within four months, following buys on 2025-05-21, 2025-03-18, 2025-03-10, 2025-03-03, and 2025-02-03. The repeated accumulation at depressed levels (current price $3.94 is -40.3% from the 52-week high of $6.60) continues a pattern, though measurable outcomes from prior PETS transactions are poor: the two prior trades with complete 90-day data showed negative 90-day returns (-14.4% and -24.9%), and neither trade proved well-timed. The underlying business remains structurally challenged: PetMed Express posted net income of $-707,000.00 over the most recent quarter and was unprofitable over its most recent full fiscal year, limiting the fundamental case for conviction despite the insider's continued accumulation at attractive price levels.

10% owner NINA CAPITAL HOLDINGS buys 25,000 shares at $3.86; stock down -45.2% from 52-week high, insider's prior PETS trades all negative at 90d

NINA CAPITAL HOLDINGS acquired 25,000 shares (1.0% increase) of PETMED EXPRESS at $3.86 on 2025-05-21, holding 2,525,000 shares post-transaction. The timing is notable: at $3.86, the purchase was well below the 52-week high of $6.60, and the stock has since declined further to $3.62 (current price, -45.2% from peak). However, the insider's track record at this specific ticker is concerning—all 5 prior trades at PETS show negative 90-day returns, including -24.9%, -24.5%, and three recent trades with immeasurable 90d outcomes but all negative 30-day returns. Across the insider's broader cross-ticker history, 10 prior open-market buys averaged -7.9% at 30 days and -13.3% at 90 days, with a 90-day win rate of only 14.29%. Fundamentally, PETMED EXPRESS remains unprofitable (net income $-707,000 in the latest quarter) despite modest annual revenue growth of +9.4%, with a compressed P/E of 181.00. The purchase does not contradict the observed pattern of poor subsequent returns on this insider's acquisitions.